发明名称 ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE
摘要 The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis.
申请公布号 US2015086567(A1) 申请公布日期 2015.03.26
申请号 US201414538673 申请日期 2014.11.11
申请人 CEDARS-SINAI MEDICAL CENTER 发明人 Gonsky Rebecca;Deem Richard;Targan Stephan R.
分类号 C12Q1/68;C07K16/24 主分类号 C12Q1/68
代理机构 代理人
主权项 1. A method of diagnosing susceptibility to an inflammatory bowel disease (IBD) subtype in an individual, comprising: (a) obtaining a sample from the individual; (b) assaying the sample to determine the presence or absence of at least one risk genetic variant at the genetic locus of IFNG; and (c) diagnosing susceptibility to the IBD subtype based on the presence of at least one risk genetic risk variant at the genetic locus of IFNG.
地址 LOS ANGELES CA US